# Rezubio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rezubio

- Industry: Biotechnology
- Headquarters: Zhuhai, China
- Website: www.rezubio.com/
- Latest round: Series A (Dec 8, 2025)
- Investors on record: 5

## About

Based in Zhuhai, China and established in 2019, Rezubio Pharmaceuticals Co., Ltd, trading as Rezubio, is a targeted drug development company, focusing on research in areas such as oncology, immunology, and metabolic diseases. The company's founder and CEO, Yusheng Xiong, has a Ph.D. in organic chemistry from the University of California, followed by a postdoctoral fellowship at the University of Chicago. He has been engaged in the development of new drugs in medicinal chemistry for more than 20 years at Merck Sharp & Dohme Pharmaceuticals. In December 2025, Rezubio raised over CNY 100 million in series A funding led by new investor Lapam Capital, with participation from new investors Frees Fund, and returning investor Riverhead Capital.

The company provides targeted drugs, such as liver and intestine-targeted drugs. It gut-restricted drug design platform for metabolic diseases, inflammatory immune diseases, and central nervous system degenerative pathologies.

The company's revenue is generated by producing targeted drugs.

## Funding rounds

- Series A, Dec 8, 2025 — Lapam Capital, Riverhead Capital, Frees Fund
- Series A, Sep 27, 2019 — Hengqin Financial Investment, Zhuhai Chengze Investment Management

## Investors

- Hengqin Financial Investment (https://capitalatlas.ai/funds/hengqin-financial-investment) — Series A
- Zhuhai Chengze Investment Management — Series A
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series A
- Riverhead Capital (https://capitalatlas.ai/funds/riverhead-capital) — Series A
- Frees Fund (https://capitalatlas.ai/funds/frees-fund) — Series A